Burden, clinical impact, and primary antimicrobial resistance profiles of Helicobacter pylori infections in Cameroon: A systematic review and meta-analysis
PLOS Global Public Health · 11.08.2026 · 6 (8) · e0006486
DOI: 10.1371/journal.pgph.0006486 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS Global Public Health, online erschienen am 11.08.2026. Verfasst von Eliane V Assokom Okoubalimba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Expertise and Research in Applied Biology (CEREBA), Douala, Cameroon. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Helicobacter pylori is one of the most widespread pathogens in humans and a strong predictor of gastric cancers. This systematic review and meta-analysis (PROSPERO: CRD420261375391) aimed at determining the extent, clinical impact, and antibiotic resistance profile of H. pylori infections in Cameroon. Six databases were exploited to identify relevant studies published between 2000 and 2026, as per PRISMA guidelines. Pooled proportions were computed using random effects models, while sensitivity analyses were performed to identify confounding factors. A total of 46 studies were included. The pooled proportion of H. pylori infection was 56.7% (95%CI 51.1 – 62.1%), with higher estimates found in i) clinical settings (57.0%), ii) the regions of Centre (62.2%) and Littoral (58.5%), iii) adults (59.7%), and individuals with gastrointestinal disorders (60.1%). The burden of H. pylori was positively correlated with gastric disease severity, with 64.5% of infection cases seen in gastric cancer. Infections have led to adverse clinical effects (e.g., anemia). H. pylori isolates were highly resistant to metronidazole (87.6%, 95%CI 62.4 – 96.8%), while the lowest resistant rates were found for levofloxacin (1.1%, 95%CI 0.4 - 3.2%) and rifampicin (0.6%, 95%CI 0.1 - 2.2%). An unusually high resistance rate to amoxicillin (93.4%; 95% CI 85.9–97.0%) was observed, warranting confirmatory studies. Multidrug-resistant isolates accounted for 77.6%. Several urgent challenges, including the lack of studies in four regions, in other at-risk groups (e.g., obese), limited clinical data, and resistance status vis-à-vis other commonly prescribed ATBs (i.e., amoxicillin), have been identified. This comprehensive study provides baseline data to improve therapeutic management and resistance stewardship in Cameroon.
Autor:innen und Institutionen
- Center for Expertise and Research in Applied Biology (CEREBA), Douala, Cameroon.
- Department of Biochemistry, Faculty of Sciences, The University of Douala, Douala, Cameroon.
- Department of Clinical Sciences, Faculty of Medicine and Pharmaceutical Sciences, The University of Douala, Douala, Cameroon.
ORCID-Profile: Loick P Kojom Foko
Zitieren
APA
Assokom Okoubalimba, E. V., Ekwe Priso, J. G. L. F., Ntatou Lemouchele, I., Kedy Koum, D. C., Koanga Mogtomo, M. L., & Kojom Foko, L. P. (2026). Burden, clinical impact, and primary antimicrobial resistance profiles of Helicobacter pylori infections in Cameroon: A systematic review and meta-analysis. PLOS Global Public Health, 6(8), e0006486. https://doi.org/10.1371/journal.pgph.0006486
Vancouver
Assokom Okoubalimba EV, Ekwe Priso JGLF, Ntatou Lemouchele I, Kedy Koum DC, Koanga Mogtomo ML, Kojom Foko LP. Burden, clinical impact, and primary antimicrobial resistance profiles of Helicobacter pylori infections in Cameroon: A systematic review and meta-analysis. PLOS Global Public Health. 2026;6(8):e0006486. doi:10.1371/journal.pgph.0006486
BibTeX
@article{AssokomOkoubalimba2026,
author = {Assokom Okoubalimba, Eliane V and Ekwe Priso, Judith G L F and Ntatou Lemouchele, Idriss and Kedy Koum, Danielle C and Koanga Mogtomo, Martin L and Kojom Foko, Loick P},
title = {Burden, clinical impact, and primary antimicrobial resistance profiles of Helicobacter pylori infections in Cameroon: A systematic review and meta-analysis},
journal = {PLOS Global Public Health},
year = {2026},
volume = {6},
number = {8},
pages = {e0006486},
doi = {10.1371/journal.pgph.0006486}
}
EUVIMED